Nov 09, 2016 5:50pm EST Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Third Quarter Ended September 30, 2016
Nov 01, 2016 8:00am EDT Pieris Pharmaceuticals to Host Third Quarter 2016 Investor Call and Corporate Update on November 10, 2016
Oct 26, 2016 8:00am EDT Pieris Pharmaceuticals to Receive GLP Tox Milestone Payment in Daiichi Sankyo Collaboration
Sep 26, 2016 5:15pm EDT Pieris Pharmaceuticals Presents Positive Data for Its Lead Bispecific Drug Candidate, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Sep 22, 2016 8:00am EDT Pieris Pharmaceuticals Appoints Christopher Kiritsy to Its Board of Directors
Sep 07, 2016 8:30am EDT Pieris Pharmaceuticals Announces Presentation of Data for Its Lead IO Bispecific Program, PRS-343, at the 2016 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Sep 01, 2016 10:31am EDT Pieris Pharmaceuticals to Present at Rodman & Renshaw 18th Annual Global Investor Conference
Aug 10, 2016 5:00pm EDT Pieris Pharmaceuticals Reports Financial Results and Provides Corporate Update for the Second Quarter Ended June 30, 2016
Aug 01, 2016 8:00am EDT Pieris Pharmaceuticals to Host Second Quarter 2016 Investor Call and Corporate Update on August 11, 2016
